An observational study in Anaerobic Infection, Infectious Enterocolitis and Amebic Dysentery, sponsored by Pfizer. Completed. Per ClinicalTrials.gov, last updated 2018-12-28.
Sponsored by Pfizer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Secondary Data Collection Study; safety and effectiveness of Anaemetro under Japanese medical practice
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients who satisfy all of the inclusion criteria are subject to this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Number of Participants With Adverse Drug Reaction (ADR)
An adverse drug reaction (ADR) was any untoward medical occurrence attributed to ANAEMETRO Intravenous infusion in a participant who received ANAEMETRO Intravenous infusion. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Relatedness to ANAEMETRO Intravenous infusion was assessed by the physician.
Time frame: Maximum 8 weeks
Clinical Response Rate
Clinical response of ANAEMETRO Intravenous infusion was evaluated comprehensively at the completion of the observation period, being assessed as "effective," "not effective," or "indeterminate" by the physician based on clinical symptoms. Clinical response rate, which was defined as the percentage of participants evaluated as "effective" over the total number of assessable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI.
Time frame: Maximum 8 weeks
Clinical Response Rates by Target Diseases
Clinical response of ANAEMETRO Intravenous infusion was evaluated comprehensively at the completion of the observation period, being assessed as "effective," "not effective," or "indeterminate" by the physician based on clinical symptoms. Clinical response rate, which was defined as the percentage of participants evaluated as "effective" over the total number of assessable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI. Participants assessed as "effective" by the following target diseases were counted to assess whether they contribute to the clinical response: anaerobic infection, infectious enterocolitis, amebic dysentery, and the infection with both infectious enterocolitis and amebic dysentery.
Time frame: Maximum 8 weeks
| Milestone | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|---|
| Started | 107 |
| Completed | 107 |
| Not completed | 0 |
An adverse drug reaction (ADR) was any untoward medical occurrence attributed to ANAEMETRO Intravenous infusion in a participant who received ANAEMETRO Intravenous infusion. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Relatedness to ANAEMETRO Intravenous infusion was assessed by the physician.
| Participants | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|---|
| ADR | 7 |
| Serious ADR | 1 |
Clinical response of ANAEMETRO Intravenous infusion was evaluated comprehensively at the completion of the observation period, being assessed as "effective," "not effective," or "indeterminate" by the physician based on clinical symptoms. Clinical response rate, which was defined as the percentage of participants evaluated as "effective" over the total number of assessable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI.
| Percentage of Participants | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|---|
| Clinical Response Rate | 95.8 (89.6 to 98.8) |
Clinical response of ANAEMETRO Intravenous infusion was evaluated comprehensively at the completion of the observation period, being assessed as "effective," "not effective," or "indeterminate" by the physician based on clinical symptoms. Clinical response rate, which was defined as the percentage of participants evaluated as "effective" over the total number of assessable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI. Participants assessed as "effective" by the following target diseases were counted to assess whether they contribute to the clinical response: anaerobic infection, infectious enterocolitis, amebic dysentery, and the infection with both infectious enterocolitis and amebic dysentery.
| Percentage of Participants | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|---|
| Anaerobic infection (n=64)excluding IND(n=10) | 93.8 (84.8 to 98.3) |
| Infectious enterocolitis (n=21) excluding IND(n=2) | 100.0 (83.9 to 100.0) |
| Amebic dysentery (n=7) | 100.0 (59.0 to 100.0) |
| Infectious enterocolitis + amebic dysentery (n=3) | 100.0 (29.2 to 100.0) |
Collected over Maximum 8 weeks. Non-serious events are listed at a 1.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ANAEMETRO Intravenous Infusion (Metronidazole) | 3/107 (2.8%) | 11/107 (10.3%) | 2/107 (1.9%) |
| Event | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|---|
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 2/107 |
| Liver disorderHepatobiliary disorders | 2/107 |
| Bronchopulmonary aspergillosisInfections and infestations | 1/107 |
| Clostridium difficile infectionInfections and infestations | 1/107 |
| PneumoniaInfections and infestations | 1/107 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 1/107 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/107 |
| Cholecystitis acuteHepatobiliary disorders | 1/107 |
| Multiple organ dysfunction syndromeGeneral disorders | 1/107 |
| Event | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|---|
| NauseaNervous system disorders | 2/107 |
A total of 107 participants were enrolled in this study. There was no participant excluded from the baseline analysis.
| Age, Customized(Participants) | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|---|
| <15 years | 0 |
| ≥15 and <65 years | 40 |
| ≥65 years | 67 |
| Sex/Gender, Customized(Participants) | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|---|
| Male | 69 |
| Female | 38 |
| Race and Ethnicity Not Collected(Participants) | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|
| Target Diseases(Participants) | ANAEMETRO Intravenous Infusion (Metronidazole) |
|---|---|
| Anaerobic infection | 74 |
| Infectious enterocolitis | 23 |
| Amebic dysentery | 7 |
| Infectious enterocolitis + amebic dysentery | 3 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jul 2015 to primary completion in Aug 2017, 25 months.
Results were first posted in Dec 2018, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dysentery, Amebic